Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry
- PMID: 18979180
- DOI: 10.1007/s10545-008-0868-z
Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry
Abstract
Gaucher disease is a lysosomal storage disorder caused by a deficiency of the enzyme acid beta-glucosidase. The most prevalent mutant genotype in type I Gaucher disease, N370S/N370S, is commonly thought to confer a mild phenotype presenting in adulthood. To characterize a subset of more severely affected N370S homozygotes, we assessed the phenotypes at or near the time of diagnosis of all N370S homozygotes with available data enrolled in the International Collaborative Gaucher Group Gaucher Registry. N370S compound heterozygotes were analyzed for comparison, as they are expected to present with a more severe phenotype. Of 798 N370S homozygotes and 1,278 N370S compound heterozygotes identified, 32% (251/788) and 65% (820/1269), respectively, were diagnosed before age 20 years. At diagnosis, N370S homozygotes as compared to N370S compound heterozygotes had the following clinical characteristics: irreversible skeletal lesions 17% (34/198) for N370S homozygotes versus 26% (76/290) for N370S compound heterozygotes; anaemia 18% (59/327) versus 29% (145/494); thrombocytopenia 52% (170/327) versus 62% (281/453); hepatomegaly 44% (83/190) versus 72% (141/195); splenomegaly 73% (142/194) versus 91% (178/195); and osteopenia or osteoporosis 48.6% (34/70) versus 51% (25/49). Some N370S homozygotes exhibited more severe clinical manifestations: 9% (29/327) had severe thrombocytopenia; 3% (5/190) had severe hepatomegaly; 11% (22/194) had severe splenomegaly; 7% (18/255) reported bone crises; 11% (8/70) had osteoporosis. In conclusion, N370S homozygosity does not consistently confer a mild, adult-onset phenotype. Gaucher disease patients with the N370S/N370S genotype exhibit a high degree of phenotypic heterogeneity and some may be at risk for early disease onset and severe clinical manifestations.
Comment in
-
Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease.J Inherit Metab Dis. 2009 Jun;32(3):453-4; author reply 455-6. doi: 10.1007/s10545-009-1114-z. Epub 2009 Mar 27. J Inherit Metab Dis. 2009. PMID: 19322674 No abstract available.
Similar articles
-
Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications.Am J Hum Genet. 1993 Jun;52(6):1094-101. Am J Hum Genet. 1993. PMID: 8503443 Free PMC article.
-
Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.Arch Intern Med. 2010 Sep 13;170(16):1463-9. doi: 10.1001/archinternmed.2010.302. Arch Intern Med. 2010. PMID: 20837833 Free PMC article.
-
Phenotypic heterogeneity in patients with Gaucher disease and the N370S/V394L genotype.Genet Test. 2005 Spring;9(1):26-9. doi: 10.1089/gte.2005.9.26. Genet Test. 2005. PMID: 15857183
-
Gaucher disease: pediatric concerns.Paediatr Drugs. 2002;4(7):417-26. doi: 10.2165/00128072-200204070-00001. Paediatr Drugs. 2002. PMID: 12083970 Review.
-
Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.Blood Cells Mol Dis. 2007 May-Jun;38(3):287-93. doi: 10.1016/j.bcmd.2006.11.003. Epub 2006 Dec 29. Blood Cells Mol Dis. 2007. PMID: 17196853 Review.
Cited by
-
Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening.Genet Med. 2017 Jun;19(6):652-658. doi: 10.1038/gim.2016.159. Epub 2016 Oct 13. Genet Med. 2017. PMID: 27735925
-
The European Gaucher Alliance: a survey of member patient organisations' activities, healthcare environments and concerns.Orphanet J Rare Dis. 2014 Sep 2;9:134. doi: 10.1186/s13023-014-0134-4. Orphanet J Rare Dis. 2014. PMID: 25178161 Free PMC article.
-
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.Am J Hematol. 2017 Sep;92(9):929-939. doi: 10.1002/ajh.24801. Epub 2017 Jul 7. Am J Hematol. 2017. PMID: 28569047 Free PMC article. Clinical Trial.
-
Disease registries and outcomes research in children: focus on lysosomal storage disorders.Paediatr Drugs. 2011 Feb 1;13(1):33-47. doi: 10.2165/11586860-000000000-00000. Paediatr Drugs. 2011. PMID: 21162599 Review.
-
The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects.Orphanet J Rare Dis. 2020 Nov 11;15(1):318. doi: 10.1186/s13023-020-01597-0. Orphanet J Rare Dis. 2020. PMID: 33176831 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical